Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Gilead Study Director
Gilead Sciences
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
288 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hospital Britanico de Buenos Aires
Buenos Aires, Argentina
- Instituto de Investigaciones Clinicas de Mar del Plata
Buenos Aires, Argentina
- Instituto Alexander Fleming
C.a.b.a., Argentina
- Hospital Alemán
CABA, Argentina
- Centro Privado de Rmi Rio Cuarto S.A.
Córdoba, Argentina
- Instituto de Oncología de Rosario
Rosario, Argentina
- Cer San Juan Centro Polivalente de Asistencia E Investigación Clínica
San Juan, Argentina
- Royal Brisbane and Women'S Hospital
Queensland, ME, Australia
- St Vincent'S Hospital Sydney
Darlinghurst, New South Wales, Australia
- Liverpool Hospital
Liverpool, New South Wales, Australia
- Genesiscare North Shore (oncology)
St Leonards, New South Wales, Australia
- Icon Cancer Centre Wesley
Auchenflower, Queensland, Australia
- Flinders Medical Centre
Bedford Park, South Australia, Australia
- Icon Cancer Centre Hobart
Hobart, Tasmania, Australia
- Austin Health
Melbourne, Victoria, Australia
- Sunshine Hospital (western Health)
St Albans, Victoria, Australia
- Breast Cancer Research Centre - Wa
Nedlands, Western Australia, Australia
- University Hospital Innsbruck
Innsbruck, Austria
- Universitätsklinik Für Innere Medizin 3 Der Pmu
Salzburg, Austria
- Medizinische Universitat Wien, Univ. Klinik Fur Innere Medizin I Klinische Abteilung Fur Onkologie
Vienna, Austria
- Klinikum Wels-Grieskirchen
Wels, Austria
- Gza Ziekenhuizen - Campus Sint-Augustinus
Antwerp, Belgium
- Az Klina
Brasschaat, Belgium
- Cliniques Universitaires Saint-Luc
Brussels, Belgium
- Universitaire Ziekenhuis Leuven
Leuven, Belgium
- Chu Ucl Namur-Site Ste. Elisabeth
Namur, Belgium
- Hospital Haroldo Juaçaba - Instituto Do Câncer Do Ceará
Fortaleza, Brazil
- Hospital Araujo Jorge - Associacao de Combate Ao Cancer Em Goias
Goiânia, Brazil
- Oncosite - Centro de Pesquisa Clinica E Oncologia
Ijuí, Brazil
- Catarina Pesquisa Clinica
Itajaí, Brazil
- Oncoclinicas Do Brasil Servicos Medicos As
Minas Gerais, Brazil
- Liga Norte-Rio-Grandense Contra O Câncer
Natal, Brazil
- Cionc-Centro Integrado de Oncologia de Curitiba
Paraana, Brazil
- Hospital Erasto Gaertner
Paraná, Brazil
- Imip - Instituto de Medicina Integral Professor Fernando Figueira
Pernambuco, Brazil
- Hgb - Hospital Giovanni Battista/mãe de Deus Center
Porto Alegre, Brazil
- Hospital São Lucas Da Pucrs
Porto Alegre, Brazil
- Hospital de Clínicas de Porto Alegre - Hcpa
Porto Alegre, Brazil
- Irmandade Da Santa Casa de Misericórdia de Porto Alegre
Porto Alegre, Brazil
- Clínica de Oncologia de Porto Alegre Ltda - Clinionco
Rio Grande, Brazil
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 8 May 2023
- Primary completion
- 30 Apr 2028
- Completion
- 30 Apr 2028
- Last update posted
- 3 Oct 2025
- Registered enrollment
- 654
- Registry id
- NCT05840211
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.